| Market Cap | 26.22B | P/E | 38.41 | EPS this Y | 300.00% | Ern Qtrly Grth | 13.50% |
| Income | 21.52B | Forward P/E | 14.03 | EPS next Y | 79.20% | 50D Avg Chg | -6.00% |
| Sales | 1.7T | PEG | 65,763.30 | EPS past 5Y | -1.49% | 200D Avg Chg | -1.00% |
| Dividend | 398.00% | Price/Book | 0.02 | EPS next 5Y | 0.11% | 52W High Chg | -14.00% |
| Recommedations | 2.00 | Quick Ratio | 0.66 | Shares Outstanding | 1.79B | 52W Low Chg | 14.00% |
| Insider Own | 0.25% | ROA | 1.82% | Shares Float | 1.73B | Beta | 0.29 |
| Inst Own | 50.74% | ROE | 1.32% | Shares Shorted/Prior | -/- | Price | 14.60 |
| Gross Margin | 81.51% | Profit Margin | 1.26% | Avg. Volume | 1,530 | Target Price | - |
| Oper. Margin | 11.27% | Earnings Date | Oct 30 | Volume | 250 | Change | -3.07% |
Astellas Pharma Inc. manufactures, markets, and imports and exports pharmaceuticals in Japan and internationally. The company provides XTANDI, a treatment for prostate cancer; XOSPATA, a treatment for patients who have relapsed or refractory acute myeloid leukemia with a FLT3 mutation; and PADCEV, a treatment for patients with metastatic urothelial cancer. It also offers Evrenzo, a treatment for anemia associated with chronic kidney disease; Betanis/Myrabetriq/BETMIGA, a treatment for overactive bladder; and Prograf and Advagraf/Graceptor/ASTAGRAF XL immunosuppressants. Th company has a research collaboration with Vivtex Corporation to evaluate Vivtex's GI-ORIS screening and formulation platform technology to support the development of novel and oral versions of a therapeutic candidate provided by Astellas; and a partnership agreement with Roche Diabetes Care Japan Co., Ltd. to develop and commercialize integrated diabetes self-management solution. The company was founded in 1923 and is headquartered in Tokyo, Japan.